Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: AZD-3199; Formoterol Fumarate

Criteria

Inclusion Criteria:

• Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.

• Men and post-menopausal women above 18 years of age.

• Reversible airway obstruction in response to classical beta2-agonist (salbutamol)

• Non/ex-smokers

Exclusion Criteria:

• Any clinically significant disease or disorder other than asthma

• Any clinically relevant abnormal findings at screening examinations

• Treatment with systemic glucocorticosteroids within the past 30 days

• Inhaled corticosteroid use if dosing is not kept constant